Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2010(2): 0141-0141
DOI: 10.1055/s-0029-1219035
DOI: 10.1055/s-0029-1219035
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag
Stuttgart ˙ New York
HCV NS5B Inhibitor PSI-6130
P. Wang, B.-K. Chun, S. Rachakonda, J. Du, N. Khan, J. Shi, W. Stec, D. Cleary, B. S. Ross*, M. J. Sofia
Pharmasset, Inc., Princeton, USA and Polish Academy of Sciences, Lodz, Poland
Further Information
Publication History
Publication Date:
21 January 2010 (online)
![](https://www.thieme-connect.de/media/synfacts/201002/lookinside/thumbnails/10.1055-s-0029-1219035-1.jpg)
Significance
PSi-6130 is a ribonucleoside analogue that is currently in phase IIb clinical trials for the treatment of hepatitis C. It is the first direct acting antiviral to display potent activity against both genotype 2 and 3 virus. A major challenge in the synthesis was the efficient installation of the C-2′ fluorinated quaternary center. This was accomplished via regioselective nucleophilic opening of the cyclic sulfate D with Me4NF.